Novavax(NVAX) is the most favorable vaccine stock
Novavax, Inc(NVAX) currently trades at $13.57 and has fallen by 4% in the past 24 hours. Novavax has emerged as a favorite for investors because of its coronavirus vaccine program. The company announced on Feb. 26 that it expected to begin clinical testing of its experimental vaccine for protecting against novel coronavirus disease COVID-19 by late spring.
Based on this information, investorsQ rates this stock a 5 out of 10. We give it this rating because Novavax’s previous experience developing vaccines for MERS and SARS, which are also members of the coronavirus family, gave it a solid foundation from which to start. The high forecast for Novavax, Inc is $24 and the low is $19. Notably, the company’s market cap is $695.13 million with a 52 week high of $17.71 and a 52 week low of $3.54.